Hashimoto’s Thyroiditis And Cancer: A Review

  • Rita Hajj Boutros AUBMC
  • Ibrahim Salti, Professor AUBMC


Background: No consensus exists on the association between Hashimoto’s thyroiditis (HT) and cancer. To resolve this controversy, this review aimed to evaluate the relationship between the two conditions.

Methods: Using Pub-Med database, we searched studies relevant to the topic focusing on the association between HT and Papillary Thyroid Cancer (PTC), as well as the association between HT and Primary Thyroid Lymphoma (PTL).

Findings: Both HT and PTC are common worldwide, and the two conditions may be closely related. However, the relationship remains controversial. Some studies found that PTC coexisted with HT 2.8-fold more frequently, with variable prevalence ranging from 0.5 to 30%. In contrast to surgical and pathological series that suggested a positive correlation between the two diseases and even a cause-and-effect relationship, the other studies evaluating fine-needle aspirate specimens did not find a statistically significant correlation. On the other hand, the relationship between PTL and HT appears well established.

Conclusion: The existing data provide inconsistent evidence favoring a causal relationship between HT and PTC. Prospective studies are needed to further elucidate the relationship. However patients with HT are at risk for PTL. Therefore careful observation and follow-up of HT patients is recommended.


1. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646–55.
2.Mazakopakis E, Tzortzinis A, Dalieraki-Ott E, et al. Coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. A retrospective study. Hormones (Athens). 2010;9:312–318.
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167.
4. Cheema Y, Olson S, Elson D, Chen H. What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J. Surg. Res 2006;134:160–162. [PubMed: 16780882]
5. Kumar Vinay (2010) ‘24: The Endocrine System’. Robbins and Cotran Pathologic Mechanisms of Disease. 8th edn. Elsevier: Philidelphia, PA, pp 1111–1205.
6. Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann. Surg. Oncol 2006;13:1524–1528. [PubMed: 17006742]
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69–90.
8. Bloodworth, JMB.; Lechago, J.; Gould, VE. Bloodworth's endocrine pathology. Baltimore, Md: Williams & Wilkins; 1997. The thyroid; p. 178-181.p. 197-206.
9. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch. Surg 1955;70:291–297. [PubMed: 13227748]
10. Konturek A, Barczynski M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto
thyroiditis. Langenbecks Arch Surg. 2013;398:389–94.
11. Replinger D et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008 November; 150(1): 49-52
12. Zhang L et al. The clinical features of papillary thyroid cancer in Hashimoto’s thyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer 2012, 12:610.
13. Matesa-Anic´ D, Matesa N, Dabelic´ N, Kusic´ Z. Coexistence of papillary carcinoma and Hashimoto’s thyroiditis. Acta Clin Croat. 2009;48:9–12.
14. Tamimi D. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol. 2002;10:141–146.
15. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact of presentation, management and outcome. Surgery. 1999; 126:1070–1077.
16. Yoon YH, Kim HJ, Lee JW, Kim JM, Koo BS. The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis. Eur Arch Otorhinoloaryngol. 2012;269:1013–1017.
17. Eisenberg BL, Hensley SD. Thyroid cancer with coexistent Hashimoto’s thyroiditis. Clinical assessment and management. Arch Surg. 1989;124:1045–1047.
18. Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71: 581–586.
19. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25: 632-7.
20. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 1995; 76: 2312-8.
21. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 458-63.
22. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998; 8: 197-202.
23. Del Rio P, Cataldo S, Sommaruga L, Concione L, Arcuri MF, Sianesi M. The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer? Minerva Endocrinol 2008; 33: 1-5.
24. Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, Izumi M, Nagataki S. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 1992; 75: 596-602.
25. Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem. 2010;17:3449–61.
26. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007;204:764–73, discussion 773–5.
27. Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol. 2004;35:465–73.
28. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology
prize lecture. Eur J Endocrinol. 2006;155:645–53.
29. Crile GJ, Hazard JB. Incidence of cancer in struma lymphomatosa. Surg Gynecol Obstet. 1962;115:101–103.
30. Mukasa K, Noh JY, Kunii Y, et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid disease. Thyroid. 2011;21: 37–41.
31. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012;97:2682–2692.
32. Epstein, M. A., Achong, B. G. and Barr, Y. M. Virus particles in cultured lympho blastsfrom Burkitt's lymphoma. Lancet, 1, 702-703 (1964).
33. de The, G. Epidemiology of Epstein-Barr viruses and associated diseases in man. In "The Herpes Viruses," ed. B. Roizman, pp. 25-103 (1982). Plenum Publishing Corp., New York and London.
34. Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D. and Gallo, R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA, 77,7415-7419 (1980).
35. Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K., Shirakawa, S. and Miyoshi, I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to antigen in human sera. Proc. Natl. Acad. Sci. USA, 78, 6476- 6480 (1981).
36. Cummings, N. A., Schall, G. L., Asofsky, R., Anderson, L. G. and Tatal, N. Sjogren's syndrome: newer aspects of research, diagnosis,and therapy. Ann. Int. Med., 75, 937- 950 (1971).
37. Kassan, S. S., Thomas, T. L., Moutsopoulos, H. M., Hoover, R., Kimberly, R. P., Budman, D. R., Costa, J., Decker, J. L. and Chused, T. M. Increased risk of lymphoma in sicca syndrome. Ann. Int. Med., 89, 888- 892 (1978).
38. Isomaki H. A. Excess risk of lymphoma, leukemia and myeloma in patients with rheumatoid arthritis. J. Chronic Dis., 31, 691-696 (1978).
39.Walt, A. J., Woolner, L. B. and Black, B. M. Small-cell malignant lesions of the thyroid gland. J. Clin. Endocrinol. Metab., 17, 45-60 (1957).
40.Woolner, M. B., McConahey, W. M. and Beahrs, O. H. Struma lymphomatosa (Hashimoto's thyroiditis) and related thyroid disorders. J. Clin. Endocrinol. Metab.,19, 53-83 (1959).
41.Burke, J. S., Butler, J. J. and Fuller, L. M. Malignant lymphomas of the thyroid.Cancer, 39, 1587-1602 (1977).
42. Compagno, J. and Oertel, J. E. Malignant lymphoma and other lymphoproliferative disorders of the thyroid gland: a clinicopathologic study of 245 cases. Am. J. Clin. Pathol., 74, 1-11 (1980).
43. Hamburger, J. I., Miller, J. M. and Kini, S. R. Lymphoma of the thyroid. Ann. Int. Med., 99, 685-693 (1983).
44. Holm FM, Blomgren H, and Lowhagen H. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med .1985;312: 601-604, 1985
45. Sangalli G, Serio G, Zampatti C, Lomuscio G, Colombo L. Fine needle aspiration cytology of primary lymphoma of the thyroid: a report of 17 cases. Cytopathology. 2001;12:257–263.
46. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–260.
47. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002; 87:105–111.
48. Pedersen RK, Pedersen NT. Primary non-Hodgkin’s lymphoma of the thyroid gland: a population based study. Histopathology. 1996; 28:25–32.
49. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24: 623–639.
50.Sarinah B, Hisham AN. Primary lymphoma of the thyroid: diagnostic and therapeutic considerations. Asian J Surg. 2010;33:20–24.
51. Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery. 2009;146: 1105–1115.
52. Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid. 1993;3:93–99.
53.Ben-Ezra J, Wu A, Shiebani K. Hashimoto’s thyroiditis lacks detectable clonal immunoglobulin and T-cell receptor gene rearrangements. Human pathology 1988; 19; 1444-1448.
54. Rosai J, Carcangiu ML, DeLellis RA. Malignant Lymphoma. In Atlas of tumour pathology, tumoursof the thyroid gland. Third series, Fascicle no.5. Washington DC: AFIP, 1992.
55. Watanabe N, Noh JY, Narimatsu H, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto’s disease. Br J Haematol. 2011;153:236–243.
56. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002; 87:105–111.
57. Wolf BC, Sheahan K, DeCoste D, et al. Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol. 1992;23: 1252–1261.
58. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis. Hum Pathol. 1988;19:1315–1326.
59. Abdul-Rahman ZH, Gogas SJ, Tooze JA, et al. T-cell lymphoma in Hashimoto’s thyroiditis. Histopathology. 1996;
60. Aozasa K, Ueda T, Katagiri S, Matsuzuka F, Kuma K, Yonezawa T. Immunologic and immunohistologic analysis of 27 cases with thyroid lymphomas. Cancer 1987; 60: 969–73.
61. Coltrera MD. Primary T-cell lymphoma of the thyroid. Head Neck 1999; 21: 160–63.
62. Dunbar JA, Lyall MH, MacGillivray JB, Potts RC. T-cell lymphoma of the thyroid. BMJ 1977; 2: 679.
63.Forconi F, Bocchia M, Marconcini S et al. CD30 positive (nonanaplastic) peripheral T-cell lymphoma of the thyroid gland. Haematologica 1999; 84: 946–8.
64.Freeman HJ. T cell lymphoma of the thyroid gland in celiac disease. Can J Gastroenterol 2000; 14: 635–6.
65. Haciyanli M, Erkan N, Yorukoglu K, Sagol O, Harmancioglu O. Primary non-Hodgkin’s T-cell lymphoma of the thyroid gland complicating Hashimoto’s thyroiditis: Case report. Thyroid 2000; 10: 717–20.
66. Mizukami Y, Michigishi T, Nonomura A et al. Primary lymphoma of the thyroid: A clinical, histological and immunohistochemical study of 20 cases. Histopathology 1990; 17: 201–9.
67. Raftopoulos I, Vanuno D, Kouraklis G. Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 3. Primary T-cell lymphoma of the thyroid arising in a background of Hashimoto’s thyroiditis. J Clin Oncol 2001; 19: 3576– 80.
68. Suzuki Y, Sakane S, Sasaki M et al. A case of primary thyroid T-cell lymphoma with infiltration of lymphoma cells in peripheral blood: Diagnosed by DNA analysis. Nippon Naibunpi Gakkai Zasshi (Folia Endocrinol) 1994; 70: 1055–62 (in Japanese).
69. Yamaguchi M, Ohno T, Kita K. (gamma)/(delta) T-cell lymphoma of the thyroid gland. N Engl J Med 1997; 336: 1391–2.
70. Kato I, Tajima K, Suchi T, et al. Chronic thyroiditis as a risk factor of 8-cell lymphomas in the thyroid gland. Jpn J Cancer Res 76: 1085-1090, 1985.
71. Young NA, Al-Saleem TI, Ehya H, Smith MR. Utilization of fineneedle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer. 1998;84:252–261.
72. Jeffers MD, Milton J, Herriot R, McKean M. Fine needle aspiration cytology in the investigation on non-Hodgkin’s lymphoma. J Clin Pathol. 1998;51:189–196.
73. Sneige N, Dekmezian R, el-Naggar A, Manning J. Cytomorphologic, immunocytochemical, and nucleic acid flow cytometric study of 50 lymph nodes by fine-needle aspiration. comparison with results obtained by subsequent excisional biopsy. Cancer. 1991;67: 1003–1007.
74. Yamashita N, Maruchi N, Mori W (1979) Hashimoto’s thyroiditis: A possible risk factor for lung cancer among Japanese women. Cancer Lett 7(1): 9–13.
75. Ito K, Maruchi N (1975) Breast cancer in patients with Hashimoto’s thyroiditis. Lancet 2(7945): 1119–1121.
76. Muller I, Pinchera A, Fiore E, Belardi V, Rosellini V, Giustarini E, Giani C (2011) High prevalence of breast cancer in patients with benign thyroid diseases. J Endocrinol Invest 34(5): 349–352.
77. Davies TF. The thyrotrophin receptors spread themselves around. J Clin Endocrinol Metabol 1994; 79: 1232–8.
78. Smyth PPA, Shering SG, Kilbane MT et al. Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast carcinoma. J Clin Endocrinol Metabol 1998; 83: 2711–6.
79. Maruchi N, Annegers JF, Kurland LT (1976) Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc 51(5): 263–265.
80. Y-K Chen et al. Cancer risk in patients with Hashimoto’s thyroiditis: a nationwide cohort study, British Journal of Cancer (2013), 109: 2496-2501
81. Nose F, Ichikawa T, Fujiwara M, Okayasu I (2002) Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 117(4): 546–551.
82. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM (2007) Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204(5): 764–775.
How to Cite
HAJJ BOUTROS, Rita; SALTI, Ibrahim. Hashimoto’s Thyroiditis And Cancer: A Review. International Archives of Medicine, [S.l.], v. 10, aug. 2017. ISSN 1755-7682. Available at: <http://imedicalsociety.org/ojs/index.php/iam/article/view/2688>. Date accessed: 05 dec. 2019. doi: https://doi.org/10.3823/2504.